Does EBV Lead to MS? PDF

All About Does EBV lead to MS? EMMAN UEL AYENI , ALI DA MCHARG, JEN JANG DEP ARTMENT OF M I C R O B I O L O G Y & I M M U N O L O GY The question ? The underlying cause of MS? CO (from...

All About Does EBV lead to MS? EMMAN UEL AYENI , ALI DA MCHARG, JEN JANG DEP ARTMENT OF M I C R O B I O L O G Y & I M M U N O L O GY The question ? The underlying cause of MS? CO (from smoking) > - 50 % of patients were smoking ↑ > - lack of ↳ hard to conclude viramin D I prominent most herpesvirus , dsRNA  The timeline 1980 1993 90 % of patients had EBU antibodies ↳ first connection blue EBV and MS 1983 they had similar + 1985 findings Reese Miller Helene Paquet > late - infection ↑risk > - > - symplomatio EBV infection  2004 2005 o pulation had been infected Go 14 nuclear antigen Reese Miller could Helene Paquet EBV directly not conclude causes Ms took advantage of longitudinal aspect of study  2018 2020 B + aleroughe and micro Reese Miller Helene Paquet solidified the link 2022 study The question ?  has individuals wouldn't 2022 paper to that ↳developed Ms W EBL helps prove published in - causation Science  The Cohort US.. military > - archived blood sample incident > baseline - sample  2022 Study Results I did not have EBV >perhaps caused by - else something tested the Reese Miller Helene Paquet  2022 Study Results sound around statistic fer seroconversion > - in YA statistically significant Helene Paquet The question ?  What is new about this study? EBV precedes Ms symptoms ↳ triggers immune response cascade Helene Paquet What is new about this study? after tection price Helene Paquet ↳ plays a role in disease initiation  What is new about this study? MS patients control Helene Paquet ofference significant rules out reversed causality  Limitations of the study ↳ timing ma severinga female majoring is > - Ms population  Currently… ---reactive wit EBV mechanisms causing Ms Yay be an underlying mechanisms that causes MS  Conclusion 1 2 3 Thank you, Questions?  References 1. Bjornevik, K.J., Cortese, M., Healy, B.C., Kuhle, J., Mina, M.J., Leng, Y., Elledge, S.J., Niebuhr, D.W., Scher, A.I., Munger, K.L., & Ascherio, A. (2022). Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science, 375(6578), 296-301. https://doi.org/10.1126/science.abj8222 2. Bjornevik K, Munz C., Cohen J.I., & Ascherio A. (2023). Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat Rev Neurol. 19(3):160-171. https://doi.org/10.1038/s41582-023-00775-5 3. Dungan, L., Dunne, J., Savio, M., Kalaszi, M., McElheron, M., Lynagh, Y., O'Driscoll, K., Roche, C., Qureshi, A., Crowley, B., Conlon, N., & Kearney, H. (2024). Disease -Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides. Neurology(R) neuroimmunology & neuroinflammation, 11(3), e200217. https://doi.org/10.1212/NXI.0000000000200217 4. Haahr, S., Plesner, A.M., Vestergaard, B.F., & Hollsberg, P. (2004). A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurologica Scandinavica, 109(4), 270–275. https://doi.org/10.1046/j.1600-0404.2003.00221.x 5. Hassani, A., Corboy, J. R., Al-Salam, S., & Khan, G. (2018). Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLOS ONE, 13(2). https://doi.org/10.1371/journal.pone.0192109 6. Hedström, A.K., Huang, J., Michel, A., Butt, J., Brenner, N., Hillert, J., Waterboer, T., Kockum, I., Olsson, T., & Alfredsson, L. (2020). High levels of Epstein–Barr virus nuclear antigen-1-3 specific antibodies and infectious mononucleosis act both independently and synergistically to increase multiple sclerosis risk. Frontiers in Neurology, 10. https://doi.org/10.3389/fneur.2019.01368 7. Lanz, T.V., Brewer, R.C., Ho, P.P., Moon, J. S., Jude, K. M., Fernandez, D., Fernandes, R.A., Gomez, A. M., Nadj, G.S., Bartley, C.M., Schubert, R.D., Hawes, I.A., Vazquez, S.E., Iyer, M., Zuchero, J.B., Teegen, B., Dunn, J.E., Lock, C.B., Kipp, L.B., Cotham, V.C., … Robinson, W.H. (2022). Clonally expanded B cells in m ultiple sclerosis bind EBV EBNA1 and GlialCAM. Nature, 603(7900), 321–327. https://doi.org/10.1038/s41586-022-04432-7 8. Levin, L. I. (2005). Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA, 293(20), 2496. https://doi.org/10.1001/jama.293.20.2496 9. Martyn, C.N., Cruddas, M., & Compston, D.A. (1993). Symptomatic Epstein-Barr virus infection and multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 56(2), 167–168. https://doi.org/10.1136/jnnp.56.2.167 10. Murray, J. (2002). Infection as a cause of multiple sclerosis. BMJ, 325(7373), 1128–1128. https://doi.org/10.1136/bmj.325.7373.1128 11. Steiner, I., Nisipianu, P., & Wirguin, I. (2001). Infection and the etiology and pathogenesis of multiple sclerosis. Current Neurology and Neuroscience Reports, 1(3), 271–276. https://doi.org/10.1007/s11910-001-0030-x 12. Sumaya, C.V., Myers, L.W., & Ellison, G.W. (1980). Epstein-Barr virus antibodies in multiple sclerosis. Archives of Neurology, 37(2), 94–96. https://doi.org/10.1001/archneur.1980.0050051005209